Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Inclusion Criteria:

   - Patients must have newly diagnosed stage I-IV, persistent or recurrent (including
   unstaged) uterine carcinosarcoma (malignant mixed mullerian tumor-MMMT or with
   ovarian, fallopian tube or peritoneal carcinosarcoma and an enrollment date prior to
   10/21/2013; pathology confirmed by site/institutional pathologist prior to enrollment)
   and be chemotherapy naïve as directed against their carcinosarcoma; unstaged patients
   (patients who have not had hysterectomy or ovarian surgery) are eligible and should be
   included as "unstaged" if the only histologic (pathology) documentation of the disease
   is a biopsy or curettage of the uterus; if these patients have documented metastatic
   disease, it should be assigned the appropriate stage (III/IV)

   - Patients may have received prior adjuvant external beam radiation therapy and/or
   vaginal brachytherapy; patients should be at least 4 weeks from the completion of
   external beam radiotherapy prior to beginning protocol chemotherapy; patients do not
   need to be delayed if receiving vaginal brachytherapy only

   - Gynecologic Oncology Group (GOG) performance status 0, 1, or 2

   - Patients must have recovered from the effects of recent surgery, radiotherapy, or
   other therapy

   - Patients must be free of active infection requiring antibiotics

   - Any hormonal therapy directed at the malignant tumor must be discontinued at least one
   week prior to beginning protocol chemotherapy; continuation of hormone replacement
   therapy is permitted

   - Platelet count greater than or equal to 100,000/mcL

   - Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL equivalent to
   Common Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 grade 1

   - Creatinine less than or equal to 1.5 times upper limit of normal (ULN), CTCAE v3.0
   grade 1

   - Bilirubin less than or equal to 1.5 times ULN (CTCAE v3.0 grade 1)

   - Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 times ULN
   (CTCAE v3.0 grade 1)

   - Alkaline phosphatase less than or equal to 2.5 times ULN (CTCAE v3.0 grade 1)

   - Serum albumin should be equal to or greater than 3 g/dL

   - Neuropathy (sensory and motor) less than or equal to CTCAE v3.0 grade 1

   - Patients must have signed an approved informed consent and authorization permitting
   release of personal health information

   - Patients of childbearing potential must have a negative serum pregnancy test prior to
   study entry and be practicing an effective form of contraception

   - Patients may have measurable disease or non-measurable disease; measurable disease is
   defined as at least one lesion that can be accurately measured in at least one
   dimension (longest dimension to be recorded); each lesion must be >= 20 mm when
   measured by conventional techniques, including palpation, plain x-ray, computed
   tomography (CT), and magnetic resonance imaging (MRI), or >= 10 mm when measured by
   spiral CT; measurable disease patients must have at least one "target lesion" to be
   used to assess progression on this protocol as defined by Response Evaluation Criteria
   In Solid Tumors (RECIST); tumors within a previously irradiated field will be
   designated as "non-target" lesions unless progression is documented or a biopsy is
   obtained to confirm persistence at least 90 days following completion of radiation
   therapy

Exclusion Criteria:

   - Patients who have received prior cytotoxic chemotherapy for management of uterine or
   ovarian carcinosarcoma

   - Patients with a history of other invasive malignancies or with a concomitant invasive
   malignancy, with the exception of non-melanoma skin cancer, if there is any evidence
   of other malignancy being present within the last five years; patients are also
   ineligible if their previous cancer treatment contraindicates this protocol therapy

   - Patients for whom radiotherapy is planned after or during chemotherapy prior to
   progression of cancer

   - Patients with known hypersensitivity to Escherichia (E.) coli-derived drug
   preparations (pegfilgrastim and filgrastim [G-CSF])

   - Patients with a known hypersensitivity to mesna or other thiol compounds

   - For enrollment prior to 10/21/2013, patients who are not biopsy proven to have
   carcinosarcoma of the uterus, fallopian tube, peritoneum or ovary; for enrollment
   after 10/21/2013, patients who are not biopsy proven to have carcinosarcoma of the
   uterus